Aim: To evaluate the efficacy of Paclitaxel-carboplatin regiment in the stage IIIB-IV, non small cell lung cancer treatment at Hanoi Oncology hospital and K Hospital from 2006 to 2010. Methods: Cohort study, a total of 65 patients (46 male, 19 female) diagnosed stage IIIB-IV, non small cell lung cancer, treated with Paclitaxel-carboplatin combination (Paclitaxel 175mg/m2/day; Carboplatin 300mg/m2/day 2 cycle 21 days). Respone evaluation after finishing treatment. Results: The median age is 58,4. The symtoms decreased after treatment, there was showing that Padltaxel- carboplatin regimen enhanced the quality of life. - Overall respone rate (Partial respone) was 31,1 percent; - Median survival time is 10,4 months (95 percent; 8,8-12). 1-year survival rate is 34,7 percent.2-year survival rate is 6,7 percent; - Side effects were not significant and shortlong. None of the patients were stopped treatment due to side effects.
- Đăng nhập để gửi ý kiến